Strongbridge Biopharma plc to Present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Health...
March 14 2017 - 7:30AM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that Matthew Pauls,
president and chief executive officer, will present at the 27th
Annual Oppenheimer Healthcare Conference and the 16th Annual
Needham Healthcare Conference. The details of the conferences
are as follows:
27th Annual Oppenheimer Healthcare
Conference Tuesday, March 21 at 9:45 am ET The Westin New
York Grand Central, New York, NY
16th Annual Needham Healthcare
Conference Wednesday, April 5 at 3:40 pm ET The
Westin New York Grand Central, New York, NY
The Company’s presentations will be webcast live and archived on
the “Events & Presentations” page in the Investor section of
the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage
biopharmaceutical company focused on the development and
commercialization of therapies for rare diseases with significant
unmet needs. Strongbridge's first commercial product is KEVEYIS®
(dichlorphenamide), the first and only FDA-approved treatment for
hyperkalemic, hypokalemic, and related variants of Primary Periodic
Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S.
through August 7, 2022. In addition to establishing this
neuromuscular disease franchise, the Company has a clinical-stage
pipeline of therapies for rare endocrine diseases. Strongbridge's
lead compounds include COR-003 (levoketoconazole), a cortisol
synthesis inhibitor currently being studied for the treatment of
endogenous Cushing's syndrome, and COR-005, a next-generation
somatostatin analog (SSA) being investigated for the treatment of
acromegaly, with potential additional applications in Cushing's
syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have
received orphan designation from the U.S. Food and Drug
Administration and the European Medicines Agency. For more
information, visit www.strongbridgebio.com.
Contacts
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Sep 2023 to Sep 2024